ICON plc (NASDAQ: ICLR) (“ICON”), a world-leading clinical research organization, announced today that its wholly-owned subsidiary, ICON Investments Six Designated Activity Company (the “Issuer”), intends to offer one or more series of senior notes (the “Notes”), in a private offering (the “Offerin…
ICON plc (NASDAQ: ICLR), a world-leading clinical research organization, today announced that all resolutions at the Annual General Meeting of the company (AGM) held on July 31, 2026 were duly passed by shareholders. These resolutions were set out in the Notice of the AGM sent to shareholders dated…
Q2 2026 saw modest revenue growth and strong net business wins, but profitability declined year-over-year. Management reaffirmed full-year guidance, citing disciplined cost management and a solid backlog, while noting ongoing industry risks and recent subsidiary divestiture.Original document: ICON…
ICON plc ICLR sits where several healthcare investment themes meet. Sponsor demand for outsourced clinical development, biotech funding, artificial intelligence and broader site access all support the company’s long-term positioning.The issue is timing. Bookings have improved, but the earnings reco…
ICON plc ICLR is facing a classic recovery-stock test. The valuation has compressed, bookings have improved and backlog is larger.The problem is that the earnings reset is not over. Investors still have to weigh better order flow against weaker 2026 expectations, margin pressure, control remediatio…
